Jasper Therapeutics (NASDAQ:JSPR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Jasper Therapeutics (NASDAQ:JSPR) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other brokerages have also recently issued reports on JSPR. HC Wainwright restated a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th. Piper Sandler began coverage on shares of Jasper Therapeutics in a research note on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 target price for the company. Finally, Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research report on Friday, May 15th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.17.

Jasper Therapeutics Stock Performance

NASDAQ:JSPR opened at $0.71 on Friday. The firm’s 50-day moving average is $0.65 and its 200-day moving average is $0.85. Jasper Therapeutics has a 52-week low of $0.32 and a 52-week high of $2.87. The company has a market cap of $23.68 million, a price-to-earnings ratio of -0.45 and a beta of 3.02.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.17. Equities analysts predict that Jasper Therapeutics will post -1.32 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Knott David M Jr grew its stake in Jasper Therapeutics by 5.8% in the fourth quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after acquiring an additional 10,000 shares during the period. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics during the 1st quarter worth about $46,000. Engineers Gate Manager LP bought a new stake in Jasper Therapeutics during the second quarter worth about $78,000. Renaissance Technologies LLC raised its stake in shares of Jasper Therapeutics by 9.0% during the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock worth $416,000 after purchasing an additional 18,683 shares in the last quarter. Finally, Panagora Asset Management Inc. acquired a new stake in Jasper Therapeutics in the fourth quarter valued at $35,000. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.